Scientific Online Resource System

Varna Medical Forum

To Screen or Not to Screen for Prostate Cancer

Tosho Ganev, Lidiya Petkova, Tony Statelov, Nikolay Evtimov

Abstract

Golden standard for prostate cancer screening are digital rectal examination, PSA screening and transrectal ultrasound. The recommendations of U.S.Preventive Services Task Force (USPSTF) are based on review of medical literature which conclude that PSA screening leads to unnecessary treatment- related complications which are not justified by the number of the saved lives because:

  • Low specifity of PSA-screening for cancer detection
  • Medical complications, caused by unnecessary procedures, because of false-positive PSA.
  • Increasing pressure to reduce the rate of growth of health care

The end point of evaluation of the effect of the screening is decreasing of cancer-specific mortality and evaluation of the quality of life of the saved men.


Keywords

screening; PSA; prostate cancer

Full Text


References

Stamey TA, et al. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med. 1987;317(15):909-16.

Semjonow A, et al. Discordance of assay methods creates pitfalls for the interpretations of prostate-specific antigen values. Prostate Suppl. 1996;7:3-16.

Thompson IM,et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or-4,0 ng per milliliter. N Engl J Med. 2004;350(22):2239-46.

Carter HB,et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA. 1992;267(16)2215-20.

Schmid HP, et al. Observations on the doubling time of prostate cancer .The use of serial prostate -specific antigen in patients with untreated disease as a measure of increasing cancer volume. Cancer. 1993;71(6):2031-40.

Arlen PM, et al. Prostate Specific Antigen Working Group.Prostate Specific Antigen Working Group guidelines on prostate specific antigen doubling time. J Urol. 2008;179(6):2181-5.

HeidenreichA.Identification of high-risk prostate cancer:role of prostate -specific antigen,PSA doubling time ,and PSA velocity. EurUrol. 2008;54(5):976-7.

Ramirez ML,et al. Cirrent applications for prostate-specific antigen doubling time. EurUrol. 2008;54(2):291-300.

O`BrientMF, et al. Pretreatment prostate- specific antigen (PSA) velocity and doubling time are associated with outcome but neither improves prediction of outcome beyond pretreatment PSA alone in patients treated with radical prostatectomy. J Clinoncol. 2009;(22):3591-7.

Vickers AJ ,et al. Systematic review of pretreatment prostate -specific antigen velocity and doubling time as predictors for prostate cancer. J ClinOncol. 2009;27(3)398-403.

Hessels D, et al. DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. EurUrol. 2003;44:8-15.

NacanishiH, et al. PCA3 molecular urine assay correlates with prostate cancer tumor volume; implications in selecting candidates for active surveillance. J Urol. 2008;179(5):1804-9.

Hessels D, et al. Predictive value of PCA3 in urinary sediments in determining clinic- patological characteristics of prostate cancer. Prostate. 2010;70(1):10-6.

Shappell SB. Clinical utility of prostate carcinoma molecular diagnostic tests. Rev Urol. 2008;10(1):44-69.

TomlinsSA, et al. Recurrent Fusion of TMPRSS2 and ETS Transcripion Factor Genes in Prostate Cancer. Science. 2005;310(5748)644-8.

Roehrborn CG, Boyle P, Gould AL, et al. Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia. Urology. 1999;53(3):581-9.

Roehrborn CG. The potential of serum prostate-specific antigen as a predictor of clinical response in patients with lower urinary tract symptoms and benign prostatic hyperplasia. BJU Int. 2004;93 Suppl 1:21-6.

Bosch JL, Bohnen AM, Groeneveld FP. Validity of digital rectal examination and serum prostate specific antigen in the estimation of prostate volume in community- based men aged 50 to 78 years: the Krimpen study. EurUrol. 2004;46(6):753-9.

Rhodes T, Girman CJ, Jacobsen SJ, et al. Longitudinal prostate growth rates during 5 years in randomly selected community men 40 to 79 years old. J Urol. 1999;161(4):1174-9.

Roehrborn CG, Boyle P, Gould AL, et al. Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia. Urology. 1999;53(3):581-9.

Roehrborn CG, McConnell J, Bonilla J, et al. Serum prostate specific antigen is a strong predictor of future prostate growth in men with benign prostati├▒ hyperplasia.

PROSCAR long-term efficacy and safety study. J Urol. 2000;163(1):13-20.

Roehrborn CG. The potential of serum prostate-specific antigen as a predictor of clinical response in patients with lower urinary tract symptoms and benign prostatic hyperplasia. BJU Int. 2004;93 Suppl 1:21-6.

Wright EJ, Fang J, Metter EJ, et al. Prostate specific antigen predicts the long-term risk of prostate enlargement: results from the Baltimore Longitudinal Study of Aging. J Urol. 2002;167(6):2484-7.

Crawford ED, Wilson SS, McConnell JD, et al. MTOPS Research Group. Baseline factors as predictors of clinical progression of benign prostatic hyperplasia in men treated with placebo. J Urol. 2006;175(4):1422-6.

Mochtar CA, Kiemeney LA, van Riemsdijk MM, et al. Prostate-specific antigen as an estimator of prostate volume in the management of patients with symptomatic benign prostatic hyperplasia. Eur Urol. 2003;44(6):695-700.

Roehrborn CG, Boyle P, Gould AL, et al. Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia. Urology. 1999;53(3):581-9.

Stamey TA, Caldwell M, McNeal JE, et al. The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years? J Urol. 2004;172:1297-301.

Bartsch G, Fitzpatrick JM, Schalken JA, et al. Consensus statement: the role of prostate- specific antigen in managing the patient with benign prostatic hyperplasia. BJU Int. 2004;93 Suppl 1:27-9.

Crawford ED, Wilson SS, McConnell JD, et al. MTOPS RESEARCH Group. Baseline factors as predictors of clinical progression of benign prostatic hyperplasia in men treated with placebo. J Urol. 2006;175(4):1422-6.

Marberger MJ, Andersen JT, Nickel JC, et al. Prostate volume and serum prostate- specific antigen as predictors of acute urinary retention. Combined experience from three large multinational placebo-controlled trials. EurUrol. 2000;38(5):563-8.

Roehrborn CG, Boyle P, Bergner D, et al. Serum prostate-specific antigen and prostate volume predict long-term changes in symptoms and flow rate: results of a four- year, randomized trial comparing finasteride versus placebo. PLESS Study Group. Urology. 1999;54(4):662-9.




DOI: http://dx.doi.org/10.14748/vmf.v3i1.1114

Refbacks

Font Size


|